证券代码：300199 证券简称：翰宇药业 公告编号：2023-045 深圳翰宇药业股份有限公司 关于举行2022年度暨2023年第一季度 网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 深圳翰宇药业股份有限公司（以下简称"公司"或"翰宇药业"）《2022年年度报告 全文》《2022年年度报告摘要》及《2023年第一季度报告》于2023年4月27日在中国 证监会指定创业板信息披露网站巨潮资讯网（http://www.cninfo.com.cn）披露。为便 于广大投资者更深入全面的了解公司情况，公司定于2023年5月10日（周三）下午 15:00-17:00举行2022年度网上业绩说明会。本次说明会将采用网络互动方式召开， 投资者可登陆"价值在线"（www.ir-online.cn）参与本次说明会。 一、召开时间、地点、方式 会议召开时间：2023年5月10日 15:00-17:00 会议地点：价值在线（www.ir-online.cn） 会议方式：网络互动方式 二、投资者参与方式 投资者可于2023年5月10日15:00-17:00通过网 ...

Group 1: R&D and Product Development - The company is advancing its dual-driven model of "R&D + integration of internal and external resources" to create competitive "innovative drugs" and "generic drugs" [2] - The HY3000 project for a COVID-19 nasal spray is progressing as planned, with Phase II clinical trials initiated in China and FDA acceptance in the U.S. [2] - The company has a rich pipeline in reproductive health, including various injection products [3] Group 2: Market Insights and Growth Potential - The global market for GLP-1 receptor agonists reached $34.56 billion in 2021, with a year-on-year growth of 39.5% in the first three quarters of 2022 [2] - The assisted reproductive industry is projected to grow to ¥85.43 billion by 2025, with a compound annual growth rate of 14.5% [3] - The company’s peptide raw material exports are expected to see significant growth as patents for key drugs expire [3] Group 3: Quality Management and Compliance - The company has completed vertical integration of its supply chain and adheres to international quality standards, achieving certifications from China GMP, FDA, and EU [4] - All employees have passed quality training, ensuring that production processes meet registration quality targets [4] - The company has 12 products that have passed or are deemed equivalent in consistency evaluation, leading in the peptide sector [4] Group 4: Strategic Planning and Future Outlook - The company aims to implement the "Hanyuxiang" strategy focusing on talent, generics, and market expansion as its three pillars [5] - It plans to enhance its core competitiveness by pushing for consistency evaluations and accelerating the launch of strategic projects [5] - The company is positioned to leverage the rapid growth of the global peptide market and develop international strategic partnerships [5]

Group 1: Company Strategy and Development - The company focuses on chronic disease medications such as diabetes, cardiovascular diseases, and multiple sclerosis to improve the quality of life and medication safety for patients [1] - The strategic development goal includes further exploration of the functionality of the cartridge injection pen developed by Chengji Pharmaceutical [1] Group 2: Product Advantages - The cartridge injection pen and injection frame offer advantages over traditional "single-use syringes + ampoules" including safety, ease of use, precise dosage, and no drug waste [1] - Chengji Pharmaceutical's solvent device has distinct advantages over traditional solvent devices, such as sterile preparation, contamination avoidance, simple operation, and safety [1] Group 3: Employee Stock Ownership Plan - The first employee stock ownership plan raised a total of up to 20 million yuan, with individual employee subscription amounts ranging from 100,000 yuan to 300,000 yuan [3] - The total number of employees participating in the plan does not exceed 140, accounting for approximately 35% of the current registered employees [3] Group 4: Sales Performance - The company continues to implement differentiated and refined management in the domestic market, focusing on the promotion of products like desmopressin and terlipressin [3] - The international market shows rapid growth in the export of raw materials and peptides, with ongoing efforts to register and expand in regulated markets such as the US and Europe [3]

Group 1: Company Strategy and Development - The company focuses on the research and development of chronic disease medications, including diabetes and cardiovascular diseases, aiming to improve the quality of life and medication safety for patients [3] - The company seeks to integrate its products with mobile internet for data management and application, expanding its service and product lines to cover chronic disease management [3] - The goal is to enhance the company's international market presence and brand recognition through capital operations in international markets [3] Group 2: Financial Performance - In the first half of 2015, the company achieved operating revenue of 265 million CNY, a year-on-year increase of approximately 69% [3] - The net profit attributable to shareholders was 89.68 million CNY, reflecting a year-on-year growth of about 82% [3] - The growth is attributed to effective product market promotion and steady development of various product lines [3] Group 3: Product Development and Regulatory Progress - The company’s new product, Eptifibatide, received drug registration approval and a new drug certificate in January 2015, with production scheduled to commence [4] - Eptifibatide is recognized as a first-line drug for antiplatelet therapy in coronary heart disease and is expected to significantly enhance the company's performance [4] - The company has made progress in international registrations, with several products obtaining necessary approvals and awaiting inspections [4] Group 4: Strategic Partnerships and Innovations - The company signed a strategic cooperation agreement with a U.S. pharmaceutical company to advance the development of a key product, enhancing its international market strategy [4] - A strategic framework agreement was established with Tencent to accelerate the wireless and network integration of its non-invasive continuous glucose monitoring system [5] - This partnership aims to improve user experience and expand market influence in the IoT and smart measurement product sectors [5]

Group 1: Company Overview - The company is Shenzhen Hanyu Pharmaceutical Co., Ltd., with stock code 300199 and abbreviation Hanyu Pharmaceutical [1]. Group 2: Investor Relations Activities - The investor relations activity took place on September 15, 2015, from 10:00 AM to 12:00 PM [2]. - Participants included representatives from various investment firms such as GF Fund, Changxin Fund, and others [2]. Group 3: Drug Approval and R&D Impact - Recent reforms in drug approval processes are expected to accelerate the speed of new product launches for the company [3]. - The company has several products in the registration process, with dozens of items currently under registration [3]. - The drug Eptifibatide, which took 10 years from project initiation to approval, is a significant new drug that will positively impact the company's performance [3]. Group 4: Future Product Launches - The company anticipates launching two new products in the coming years, which are expected to contribute significantly to revenue growth [3]. - The company has made steady progress in international product registrations, with several products undergoing FDA inspections [3]. Group 5: Strategic Collaborations - A strategic cooperation agreement was signed with Akorn Pharmaceuticals for the development of Acetylglutamyl, which is expected to enhance the company's international market presence [4]. - The collaboration aims to improve the company's brand recognition and expand its international sales framework [4]. Group 6: Innovative Products - The company is developing a non-invasive continuous glucose monitoring device, GlucoPred, which has received approval for Phase III clinical trials in Norway [4]. - The device aims to improve the quality of life for diabetes patients by providing real-time glucose data and reducing the risk of long-term complications [4].

Group 1: Sales Performance - The sales of customer peptides have grown rapidly this year due to the company's increased expansion into overseas markets [2] - The sales of Teli pressure agents have entered a new stage, with further sales scale expected to emerge [2] Group 2: Technological Advantages - Chengji Pharmaceutical has unique advantages in the domestic medical device and pharmaceutical fields, focusing on "automatic injection technology" [2][3] - The company has developed proprietary products such as cartridge injection pens and combined drug dissolvers, which enhance medication safety and ease of use compared to traditional methods [3] Group 3: Cost Advantages - Chengji Pharmaceutical's geographical location provides cost advantages in land, energy, labor, and management compared to peers in the eastern coastal regions [3] - The acquisition of Chengji Pharmaceutical will facilitate the national layout of the company's production bases, with Shenzhen focusing on high-value-added formulations and Tianshui on low-value-added formulations [3]

证券代码: 300199 证券简称:翰宇药业 深圳翰宇药业股份有限公司 投资者关系活动记录表 编号: 2014-006 | --- | --- | --- | |------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | □特定对象调研 | □分析师会议 | | 投资者关系 | □媒体采访 | 口亦镇说明会 | | 活动类别 | 口新闻发布会 | ...